SENSE OF SMELL IN ADULTS

DUPIXENT DELIVERED RAPID AND SUSTAINED
IMPROVEMENT IN SENSE OF SMELL^1-5

LOSS OF SMELL SCORE

AS EARLY AS
DAY 3

RAPID
IMPROVEMENT¹

(Patient-reported outcome. Post hoc analysis. Results are
descriptive. Definitive conclusions cannot be made.)^1,2,a,b

SINUS-52: significant improvement was observed as
early as Week 4³

Week 52

SUSTAINED IMPROVEMENT THROUGH WEEK 52³

-1.10 (95% CI: -1.31, -0.89) LSM difference for DUPIXENT + INCS
(n=150) vs placebo + INCS (n=153)^3,b

Analysis was not multiplicity controlled. Results are descriptive.⁴

^aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.12, -0.02).^1,5

^bWeek 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.98
(95% CI: -1.15, -0.81) (-1.21 from a baseline score of 2.77 vs -0.23 from a baseline score of 2.72, respectively) (P<0.0001).⁴

Loss of Smell (LoS) score (range 0-3); reduced score indicates improvement.³

Improvement in % of patients with UPSIT score >18 through Week 52^4,c

UPSIT

DUPIXENT® (dupilumab) clinical trials showed a 54% improvement in nasal congestion score at week 52 in chronic rhinosinusitis with nasal polyposis patients vs. 16% improvement with placebo

72%

HAD UPSIT
SCORE >18
AT WEEK 52

vs 25% with placebo

Proportion of patients with
UPSIT score >18

Weeks

DUPIXENT 300 mg Q2W + INCS (n=150)

Placebo + INCS (n=153)

Analysis was not multiplicity controlled. Results are descriptive. Definitive conclusions cannot be
made.⁴

UPSIT score classification:
anosmia (complete loss of
smell) (≤18), severe microsmia
(19-25), moderate microsmia
(26-30),
mild microsmia
(31-34), normosmia (normal
smell appreciation) (35-40).⁴

^c Week 24 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295,
pooled arms) and placebo + INCS (n=153): 10.52 (95% CI: 8.98, 12.07) (9.71 from a baseline score of 13.53 vs -0.81
from a baseline score of 13.78, respectively) (P<0.0001).⁴

University of Pennsylvania Smell Identification Test (UPSIT) score (range 0-40): higher score indicates improvement.⁴

INCS, intranasal corticosteroid; LSM, least squares mean; Q2W, once every 2 weeks.

Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.³

Back to efficacy and safety overview

See Nasal Congestion Results